The Chemours Company (BMV:CC)
| Market Cap | 31.21B +6.0% |
| Revenue (ttm) | 105.30B +0.1% |
| Net Income | -2.78B |
| EPS | -19.55 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 6.32 |
| Dividend | 6.13 (2.24%) |
| Ex-Dividend Date | Nov 16, 2026 |
| Volume | n/a |
| Open | 274.00 |
| Previous Close | 274.00 |
| Day's Range | 274.00 - 274.00 |
| 52-Week Range | 200.00 - 454.17 |
| Beta | 1.47 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 2, 2026 |
About The Chemours Company
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The Thermal & Specialized Solutions segment provides refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents under the Freon and Opteon brand names. The Titanium Technologies segment offers TiO2 pigment, a white pigment that del... [Read more]
News
Kaplan Fox Alerts The Chemours Company (CC) Investors to an Approaching Lead Plaintiff Deadline on December 7, 2026
New York, New York--(Newsfile Corp. - November 20, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (...
The Chemours Company Announces Retirement of Kristine Wellman and Appointment of Amy Rocklin as General Counsel
WILMINGTON, Del., Nov. 18, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutio...
What Does The Chemours Company's 18.63% Stock Drop Mean for Investors? The Law Offices of Howard G.
Suit alleges The Chemours Company failed to disclose key facts to investors from February 20, 2026 through August 4, 2026; lead plaintiff deadline is December 7, 2026 BENSALEM TOWNSHIP, Pa., Nov. 17, ...
What Should The Chemours Company Investors Know After 18.63% Stock Drop? The Law Offices of Frank R.
Lawsuit alleges The Chemours Company made misleading statements to investors from February 20, 2026 to August 4, 2026; lead plaintiff motions are due December 7, 2026 LOS ANGELES, Nov. 16, 2026 /PRNew...
Kaplan Fox Reminds The Chemours Company (CC) Investors to Seek a Leadership Role Before Deadline on December 7, 2026
New York, New York--(Newsfile Corp. - November 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (...
Kaplan Fox Notifies Investors of The Chemours Company (CC) of the Lead Plaintiff Deadline on December 7, 2026
New York, New York--(Newsfile Corp. - November 12, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (...
Kaplan Fox Urges The Chemours Company (CC) Investors to Contact the Firm Before the Deadline on December 7, 2026
New York, New York--(Newsfile Corp. - November 10, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (...
CC Investor Notification: Chemours Sued for Securities Fraud on behalf of Investors with Losses after Opteon Demand Issues Lead to 18% Stock Drop
Chemours has been sued for securities fraud after its stock plummeted 18.63% because Chemours allegedly misrepresented the strength of demand for its Opteon products. NEW YORK, Nov. 10, 2026 /PRNewswi...
CC Shareholders Have Rights ā If You Lost Money Investing in The Chemours Company Contact Robbins LLP About Recovering Your Losses
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firmĀ Robbins LLPĀ reminds investors that a class action was filed on behalf of persons or entities who purchased or otherwise acquire...
Chemours price target lowered to $14 from $15 at JPMorgan
JPMorgan lowered the firmās price target on Chemours (CC) to $14 from $15 and keeps a Neutral rating on the shares. The company faces near-term demand challenges following a periodā¦
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of December 7, 2026 in The Chemours Company Lawsuit - CC
Time-Sensitive: Allegations Focus on 2026 EBITDA Guidance Representations. The lawsuit asserts that Chemours reaffirmed a full-year outlook that allegedly ignored aftermarket prebuy activity, which pu...
Chemours price target lowered to $15 from $16 at UBS
UBS lowered the firmās price target on Chemours (CC) to $15 from $16 and keeps a Neutral rating on the shares.
The Chemours Company Earnings Call Transcript: Q3 2026
Q3 sales rose 3% YoY and Adjusted EBITDA reached $200 million, with TT pricing and APM Performance Solutions growth offsetting TSS softness. FY2026 Adjusted EBITDA guidance is $775 million-$800 million, while 2027 earnings growth is expected.
The Chemours Company Earnings release: Q3 2026
The Chemours Company released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
The Chemours Company Slides: Q3 2026
The Chemours Company has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
The Chemours Company Quarterly report: Q3 2026
The Chemours Company has published its Q3 2026 quarterly earnings report on November 3, 2026.
The Chemours Company Reports Third Quarter Results
WILMINGTON, Del., Nov. 2, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solution...
Chemours Launches Faizeon⢠Two-Phase Liquid Cooling Solutions for AI Data Centers
New Faizeon⢠portfolio of two-phase direct-to-chip and immersion cooling fluids address rising AI heat loads with superior performance and reduced energy and water use WILMINGTON, Del., Nov. 2, 2026 ...
Kaplan Fox Encourages The Chemours Company (CC) Investors to Contact the Firm Before the Deadline on December 7, 2026 for a Leadership Role
New York, New York--(Newsfile Corp. - November 2, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (N...
CC Shareholders Have Rights ā If You Lost Money Investing in The Chemours Company Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firmĀ Robbins LLPĀ reminds investors that a class action was filed on behalf of persons or entities who purchased or otherwise acquire...
Kaplan Fox Advises The Chemours Company (CC) Investors to Act Before the Lead Plaintiff Deadline on December 7, 2026
New York, New York--(Newsfile Corp. - October 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (N...
Chemours Announces Fourth Quarter Dividend
WILMINGTON, Del., Oct. 27, 2026 /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE: CC) today announced that the Board of Directors of Chemours declared a quarterly cash dividend of $0.0875 per s...
Chemours Announces Dates for Third Quarter 2026 Earnings Release and Webcast Conference Call
WILMINGTON, Del., Oct. 21, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC) today announced that the Company expects to issue its third quarter 2026 financial results...
CC Loss Notice: Chemours Investors are Reminded of the December 7 Court Deadline ā Contact BFA Law if You Lost Money
NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Leading securities law firmĀ Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE:CC) and cert...
Chemours price target lowered to $20 from $24 at Truist
Truist lowered the firmās price target on Chemours (CC) to $20 from $24 and keeps a Buy rating on the shares as part of a broader research note previewing Q3ā¦